系统生物学支持的NF-κΒ和BCL2的向克服了DLBCL中微环境介导的BH3-模拟性抵抗
bioRxiv : the preprint server for biology
|December 16, 2024
概括
由于蛋白质冗余,扩散性大B细胞淋巴瘤 (DLBCL) 的向治疗是复杂的. 结合分子分析和计算建模,发现了BCL2和NF-κB抑制的漏洞,克服了抵抗机制.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 计算生物学 计算生物学
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 的特征是抗亡性BCL2家族蛋白和NF-κB子单元的升高,导致预后不佳.
- 治疗策略因异质蛋白表达,调控复杂性和功能冗余而复杂化.
- 确定精确的治疗漏洞对于有效治疗DLBCL至关重要.
研究的目的:
- 通过整合多omics数据和计算建模,识别分散型大B细胞淋巴瘤 (DLBCL) 的治疗漏洞.
- 研究DLBCL中对BCL2家族蛋白抑制的抵抗机制,特别是在瘤微环境中.
- 评估联合向疗法的疗效,包括BCL2和NF-κB抑制,以克服耐药性.
主要方法:
- 利用流式细胞计"指纹",免疫光成像和计算建模的综合工作流.
- 研究DLBCL细胞系和与CD40L表达性树皮细胞共培养的抗性机制,模仿瘤微环境 (TME).
- 采用经过实验验证的计算模型,以了解NF-κB激活在治疗耐药性的作用.
主要成果:
- 综合方法预测了对BCL2抑制 (venetoclax) 和非正规NF-κB抑制 (Amgen16) 的选择性反应.
- 在细胞亚群中确定了对BCL2抑制的独特抵抗机制,重述了内异质性.
- 证明瘤微环境成分通过细胞类型特定的BCLXL或MCL1上调调节,由NF-κB活性调节,诱导对BH3-模拟剂的耐药性.
- 表明非正规NF-κB抑制克服异质补偿BCL2上调,恢复对BH3-模拟剂的敏感性.
结论:
- 结合分子指纹和计算建模,为DLBCL中精确使用BH3-模拟剂和NF-κB抑制剂提供了一种策略.
- 了解NF-κB信号传递,瘤微环境和BCL2家族蛋白之间的相互作用是克服治疗耐药性的关键.
- 针对非正规NF-κB通路可以有效地解决DLBCL中的异质抵抗机制.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
NF-κB-dependent Signaling Pathway
7.2K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.2K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
115
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
115


